Pegsitacianine (ONM-100)

Pegsitacianine (ONM-100) is an injectable dye that surgeons give patients before cancer surgery to light up tumor tissue in real time [1]. It works on a pH switch: normal tissue sits around pH 7.4, but the microenvironment inside solid tumors is more acidic (roughly pH 6.5-6.9) because tumor cells burn glucose inefficiently and dump lactate into the surrounding tissue. Pegsitacianine's polymer chains stay bundled and dark at normal pH; when they hit acidic tumor tissue, the bundle falls apart and releases a near-infrared fluorescent signal that a surgical camera can see through blood and fat. The pitch: help surgeons find and remove tumor tissue they'd otherwise miss, which matters most in indications where the surgeon often leaves residual tumor at the edges of what they remove (positive margins) and repeat surgery is punishing (peritoneal disease, head and neck cancer, lung nodules). Currently Phase 2 across multiple indications, not FDA-approved, developed by OncoNano Medicine. FDA granted Breakthrough Therapy Designation in January 2023 for the peritoneal cytoreductive-surgery indication [6].

Not FDA-approved and not commercially available. Pegsitacianine sits in Phase 2 across three indications with mixed regulatory momentum. The active trial is ILLUMINATE (NCT05576974), a Phase 2a single-dose open-label study in patients with head and neck squamous cell carcinoma where the primary tumor site is unknown [2]. Sponsor of record is UT Southwestern; the drug is provided by OncoNano Medicine. Enrollment target is 120; the study started April 2024, is currently active/recruiting, with study completion listed as December 31, 2027 (primary completion not separately posted) [2]. Two prior Phase 2 studies have completed: NCT04950166 in peritoneal metastases after cytoreductive surgery (final publication reports 40 evaluable patients, sponsored by OncoNano) [3], and NCT05048082 in lung malignancies (n=24) [4]. FDA granted Breakthrough Therapy Designation in January 2023 for the peritoneal indication [6]. No Fast Track designation is publicly reported, and no BLA, NDA, or PMA filing has been announced. CMS coverage does not apply. This is a pre-approval intraoperative imaging agent, not an ordered lab test. Regulatory path is unresolved: intraoperative fluorescence agents typically go through NDA under CDER (as pafolacianine did in 2021), not through CDRH device pathways [5]. Any physician access today runs through the ILLUMINATE trial site.

The core is a pH-sensitive micelle: a self-assembled cluster of amphiphilic polymer chains, each tipped with a near-infrared fluorophore. At normal blood pH (around 7.4), the chains pack tightly and the fluorophores quench each other, meaning the dye is essentially dark [4]. In the acidic tumor microenvironment (pH roughly 6.5-6.9, produced by the Warburg effect where tumor cells generate lactate faster than surrounding tissue can clear it), the polymer chains protonate, the micelle disassembles, and the fluorophores separate enough to emit near-infrared light around 820 nm. Surgeons image this signal with standard near-infrared fluorescence surgical cameras (Stryker's SPY-PHI, Karl Storz's D-Light, etc.). Sample type: none in the diagnostic-lab sense. The drug is given intravenously the day before surgery and imaged in vivo during the procedure. The mechanism is tumor-agnostic in principle: any solid tumor with an acidic microenvironment should activate the probe. That is the differentiation versus pafolacianine (folate receptor-targeted, so only lights up FRα-positive tumors) and indocyanine green (non-targeted, lights up perfused tissue including lots of non-tumor). The tradeoff is specificity: acidic pH shows up in inflammation, infection, and healing tissue too, which is a real concern for post-surgical or previously biopsied fields.

The peritoneal metastases study (peritoneal carcinomatosis is diffuse tumor seeding across the lining of the abdominal cavity, most often from GI or gynecologic primaries) is the most complete dataset. In 40 evaluable patients undergoing cytoreductive surgery (debulking operations aimed at removing all visible tumor from the abdomen), pegsitacianine imaging produced a clinically significant event (CSE, defined as detection of histologically confirmed residual disease or a revision in the completeness-of-resection assessment) in 20 patients (50%), meeting the pre-specified primary endpoint [3]. Enrollment spanned six primary tumor types: appendiceal, colorectal, endometrial, mesothelioma, ovarian, and pancreatic, which is useful evidence that the pH-activation mechanism generalizes across histologies. Safety was clean: no drug-related serious adverse events across the completed studies, and transient non-anaphylactic infusion reactions in roughly 28% of patients, all self-limited [3][6]. What the trial did not do is prove that finding these extra lesions changed survival or recurrence rates. That is the classic intraoperative imaging problem: analytical detection (the dye lights up tumor) is far easier to demonstrate than clinical utility (patients live longer or recur less). The Phase 2 lung study (n=24) showed feasibility of intraoperative detection but was small and single-arm [4]. The ILLUMINATE head/neck study is investigating a specific use case: unknown primary head and neck cancer, where clinicians know a patient has metastatic disease in a neck lymph node but cannot find the primary tumor. Standard workup involves panendoscopy (endoscopic examination of the upper aerodigestive tract under general anesthesia) with blind biopsies of common primary sites (tonsil, base of tongue, nasopharynx). If pegsitacianine can localize an occult primary intraoperatively, it would meaningfully reduce the surgical burden and diagnostic ambiguity of this workup [1][2]. That is a genuinely useful niche if the data holds up.

The intraoperative fluorescence imaging market has one FDA-approved tumor-targeted agent, and it has been a commercial disappointment. Pafolacianine (Cytalux, OnTarget Laboratories, approved November 2021 for ovarian cancer and December 2022 for lung cancer) targets folate receptor alpha and requires the tumor to overexpress FRα [5]. OnTarget is privately held so exact revenue is not disclosed, but the launch trajectory has been slow, driven by narrow patient selection, workflow friction (drug must be given 1-9 hours before surgery), reimbursement complexity, and surgeon adoption inertia. On reimbursement specifically: intraoperative fluorescence agents fall between chairs. There is no dedicated CPT code for tumor-targeted fluorescence-guided surgery; the drug itself is billed under a Q or J HCPCS code (Cytalux uses Q9982), but the imaging work is bundled into the base surgical CPT and hospitals cannot charge separately for the fluorescence visualization step. That leaves the hospital eating the drug cost against whatever pass-through payment CMS grants, which for a niche indication is often insufficient to offset acquisition cost. Indocyanine green (ICG), the workhorse near-infrared dye, is generic, cheap, and used routinely for perfusion, sentinel lymph node mapping, and biliary imaging, but it is not tumor-specific and creates a high false-positive floor. Pegsitacianine's positioning claim is tumor-agnostic activation via pH, avoiding the biomarker-selection bottleneck that constrains Cytalux. Whether that translates to real specificity in humans across tumor types is still an open question given the peritoneal data. Commercial infrastructure is limited: OncoNano Medicine is a private clinical-stage biotech (Dallas-based). Last disclosed financing was a ~$68.4M Series B closed 2021 (Advantech Capital led, with a $18.4M equity conversion from CPRIT) [7]; no subsequent round has been publicly announced, so runway to a Phase 3 registration study is a real question. Pegsitacianine would need either a partnership with an established surgical device company or a significant capital raise to build sales into hospital operating rooms. No revenue today. No direct commercial competition beyond ICG and Cytalux. The addressable market is real but historically slow to convert.

Interesting mechanism, clean Phase 2 primary endpoint, unresolved commercial thesis. The pH-activation approach is scientifically clean and does solve a real limitation of receptor-targeted agents. The 50% CSE rate across six tumor types in the peritoneal study, combined with a Breakthrough Therapy Designation, is a materially stronger data package than most surgical imaging agents at the same stage. But intraoperative fluorescence imaging has been a graveyard of promising Phase 2 readouts that failed to translate into the reimbursement and adoption that support commercial success. Cytalux is the reference case: on the market for four years, technically works, commercially inert. Three things would change this trajectory: 1. ILLUMINATE (NCT05576974) delivering a compelling primary tumor localization rate in unknown primary head and neck cancer, an indication with real clinical urgency and a small, definable surgical community that can adopt fast. Study completion is listed as December 31, 2027, so meaningful data is likely 2027 or later absent an interim readout [2]. 2. A registrational Phase 3 in peritoneal metastases with a recurrence-free survival endpoint, which would take years but is the type of evidence that flips reimbursement. Breakthrough Therapy Designation streamlines FDA interactions but does not solve the capital question. 3. A partnership or acquisition by a surgical device or imaging company (Stryker, Medtronic, Intuitive) that provides the sales infrastructure OncoNano currently lacks. Absent an announced Phase 3 or a new financing round, this remains a scientifically interesting Phase 2 asset at a private biotech with no clear near-term commercial catalyst. For an investor, the risk is not the biology, it is the well-documented pattern of surgical imaging agents that reach approval and never earn back their development cost. This is not investment advice.

Our model estimates a 4% chance this drug is eventually approved. It starts from the historical base rate for Phase 2 drugs in this area (about 13%), then adjusts using ten facts about the trial and sponsor. What moves the number most: it is helped by a non-randomized design and its light or open-label blinding; it is held back by the sponsor's thin or weak approval record and weak or limited earlier-phase results. The other facts land near average for this stage, so they leave the estimate roughly where the base rate put it.